Evidence map›Paper›PMID 41972171›Full record

ArticleFrontiers in immunology2026

Baseline Th17/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasis.

Nan Yang, Zeyu Chen, Yuxiong Jiang, Jiangluyi Cai, Lian Cui, Yuanyuan Wang, Suyang Lin, Ling Wu, Qian Du, Jun Gu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nan Yang *Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Zeyu Chen *Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Yuxiong Jiang *Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Jiangluyi CaiDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Lian CuiDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Yuanyuan WangDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Suyang LinDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Ling WuDepartment of Dermatologic Surgery, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Qian DuDepartment of Dermatologic Surgery, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Jun GuInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
Yu GongInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
Qian YuDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Yuling ShiDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Psoriasis is a T cell-mediated inflammatory skin disease, and biologics have demonstrated promising efficacy. However, some patients remain dissatisfied with early therapeutic outcomes. Immune checkpoint molecules on T cells play critical roles in psoriasis pathogenesis, yet their impact on therapeutic response remains unclear. This study aimed to identify predictive markers for the early therapeutic efficacy of ixekizumab in psoriasis patients. Methods: Twenty-two patients with plaque psoriasis were enrolled in this study. All participants received ixekizumab for 24 weeks. Peripheral blood was collected at multiple time points, and flow cytometry was used to assess T cell subsets and the expression of immune checkpoint molecules, including T cell immunoreceptor with Ig and ITIM domains (TIGIT), lymphocyte activating gene 3 (LAG-3), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), B and T lymphocyte-associated protein, endothelial protein C receptor (PROCR), podoplanin (PDPN), programmed cell death 1 (PD-1), and B7-Homolog 6 (B7-H6). Results: Ixekizumab treatment reduced the proportion of T helper 17 (Th17) cells and IL-17-secreting CD8 Conclusion: Ixekizumab treatment may restore immune dysregulation in psoriasis patients. Baseline proportions of Th17 and Tc17 cells, along with LAG-3 expression on CD4

Indexed as

Antibodies, Monoclonal, HumanizedAntigens, CDDermatologic AgentsPsoriasisTh17 CellsAdultBiomarkersFemaleHumansInterleukin-17Lymphocyte Activation Gene 3 ProteinMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedAntigens, CDBiomarkersDermatologic AgentsInterleukin-17ixekizumabLag3 protein, humanLymphocyte Activation Gene 3 Proteincandidate exploratory markersixekizumabLAG-3psoriasisTc17cellsTh17 cells

Identifiers

PMID41972171
PMCPMC13066243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.